{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-016846","form_type":"8-K","ticker":"KZR","cik":"0001645666","company_name":"Kezar Life Sciences, Inc.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.517587+00:00","generated_at":"2026-06-24T00:53:45.159301+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kezar Q2 2022: Net loss $16.2M, cash $306.8M; positive Phase 2 lupus nephritis data","bullets":["Positive MISSION Phase 2 topline: 64.7% ORR, 35.2% CRR in lupus nephritis patients.","Cash, cash equivalents and marketable securities totaled $306.8M as of June 30, 2022 (up from $208.4M year-end 2021).","Net loss for Q2 2022 was $16.2M ($0.25 per share) vs $13.0M in Q2 2021.","Appointed Nick Mordwinkin, Pharm.D., Ph.D. as Chief Business Officer in July 2022.","R&D expenses $11.3M (+$2.0M YoY); G&A $5.0M (+$1.3M YoY)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-016846","json":"https://secwatch.observer/filing/0000950170-22-016846.json","markdown":"https://secwatch.observer/filing/0000950170-22-016846.md","text":"https://secwatch.observer/filing/0000950170-22-016846.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645666/000095017022016846/0000950170-22-016846-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645666/000095017022016846/kzr-20220811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:53:45.159301+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}